Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Vyome HoldingsHIND +4.02%11 EV-to-OCF is -1.42 as of Jul. 29, 2026. GuruFocus rates HIND with a GF Score™ of 11/100. The stock has 2 warning signs investors should review. Among 1,408 Biotechnology companies, Vyome Holdings ranks worse than 61.15% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Vyome Holdings's Enterprise Value is $7.05 Mil.
Vyome Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 was $-4.98 Mil. Therefore, Vyome Holdings's EV-to-OCF for today is -1.42.
The historical rank and industry rank for Vyome Holdings's EV-to-OCF or its related term are showing as below:
HIND'
s EV-to-OCF Range Over the Past 10 Years
Min: -163.77 Med: -3.18 Max: -1.04
Current: -1.42
During the past 4 years, the highest EV-to-OCF of Vyome Holdings was -1.04. The lowest was -163.77. And the median was -3.18.
HIND's EV-to-OCF is ranked worse than 61.15% of 1408
companies
in the Biotechnology industry
Industry Median: -3.235
vs HIND: -1.42
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Vyome Holdings's PE Ratio (TTM) for today is calculated as:
Vyome Holdings's share price for today is $2.07.
Vyome Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.505.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Vyome Holdings EV-to-OCF Related Terms
Vyome Holdings EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Vyome Holdings's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Vyome Holdings's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vyome Holdings EV-to-OCF vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Vyome Holdings's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Vyome Holdings's EV-to-OCF falls into.
Vyome Holdings's current Enterprise Value is $7.05 Mil.
Vyome Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.98 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vyome Holdings (HIND) has a EV-to-OCF of -1.42 as of Jul. 29, 2026. According to the industry distribution chart, Vyome Holdings ranks #861 out of 1408 companies in the Biotechnology industry, placing it in the top 61.2%.
Is Vyome Holdings' EV-to-OCF too high?
Vyome Holdings' current EV-to-OCF is -1.42. Based on the distribution chart, Vyome Holdings ranks #861 out of 1408 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Vyome Holdings has a GF Score™ of 11/100, reflecting its overall financial health beyond just this single metric.
How does Vyome Holdings' EV-to-OCF compare to CTXR and MBRX?
According to the Biotechnology industry distribution chart, Vyome Holdings ranks #861 out of 1408 companies for EV-to-OCF. This places Vyome Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Biotechnology company?
A good EV-to-OCF depends on the Biotechnology industry context. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. Vyome Holdings's current EV-to-OCF is -1.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vyome Holdings stock overvalued right now?
Vyome Holdings (HIND) has a current EV-to-OCF of -1.42. The current EV-to-OCF is -1.42. Vyome Holdings' overall GF Score™ is 11/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Vyome Holdings (HIND), the current EV-to-OCF is -1.42 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Vyome Holdings Inc is a clinical-stage specialty pharmaceutical company working to treat immune-inflammatory and rare diseases of unmet need with next-generation therapeutic solutions. Its product candidates are: VT-1953, a topical gel that is being developed to treat signs and symptoms of malignant fungating wounds in cancer; VT-1908, a repurposed immune modulator to treat steroid-sparing anterior uveitis; and VB1953, which is being developed to treat moderate to severe acne. Vyome has also commercialized two novel reformulated topical anti-fungal products based on the technology platform of Molecular Replacement Therapeutics (MRT) in India: a dandruff lotion and shampoo. It operates in two segments: pharmaceutical products, which generate the maximum revenue, and biotechnology.
11GF Score
Get the complete analysis for HIND
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HIND has been successfully added to your 
